Also trades as: 0LB2.L (LSE) · $vol 0M
SUPN NASDAQ
Supernus Pharmaceuticals, Inc.
1W: -0.7%
1M: -8.2%
3M: -12.1%
YTD: -17.2%
1Y: -22.5%
3Y: +68.5%
5Y: +38.1%
$40.96
+0.19 (+0.47%)
Weekly Expected Move ±6.0%
$36
$38
$41
$43
$46
Credit Risk of going bust: lower than 91% of companies Debt: 1.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.9%), Supernus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $40.2M against a stock market value of $2.38B.
Distance to default 14.35 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.7M (short-term plus half of long-term), stock volatility 37.6%; Altman Z 4.68. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99.9%), Supernus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $40.2M against a stock market value of $2.38B.
Distance to default 14.35 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $10.7M (short-term plus half of long-term), stock volatility 37.6%; Altman Z 4.68. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships13
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-10-12
Earliest Filing
2025-07-31
Latest Filing
target: 4
acquirer: 4
partner: 3
licensee: 2
Counterparties (Filed by SUPN)
13 relationshipsCompanies named in SUPN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sage Therapeutics, Inc. | — | target | Target company acquired in a merger agreement | 2025-07-31 | View |
| Saphire, Inc. | — | acquirer | Wholly-owned subsidiary of Supernus acting as the Purchaser in the merger | 2025-07-31 | View |
| Equiniti Trust Company, LLC | — | partner | Rights agent and depositary for the contingent value rights agreement | 2025-07-31 | View |
| Sage Therapeutics, Inc. | SGTX | target | Target company in a merger agreement where Supernus Pharmaceuticals will acquire it via a tender offer. | 2025-06-16 | View |
| Saphire Inc. | — | acquirer | Wholly-owned subsidiary of Supernus Pharmaceuticals acting as the Purchaser in the merger agreement. | 2025-06-16 | View |
| Biogen, Inc. | BIIB | partner | Collaboration partner with Supernus Pharmaceuticals for the Zurzuvae product in the United States. | 2025-06-16 | View |
| Shionogi & Co., Ltd. | SGIOF | partner | Collaboration partner of Sage Therapeutics for the Zurzuvae product in Japan. | 2025-06-16 | View |
| Apotex Inc. | — | licensee | Settlement and license agreement to market generic Oxtellar XR | 2023-06-23 | View |
| Apotex Corp. | — | licensee | Settlement and license agreement to market generic Oxtellar XR | 2023-06-23 | View |
| Adamas Pharmaceuticals, Inc. | ADMA | target | Target company acquired via tender offer and merger | 2021-11-24 | View |
| Supernus Reef, Inc. | — | acquirer | Wholly owned subsidiary of Supernus Pharmaceuticals, Inc. that executed the merger | 2021-11-24 | View |
| Adamas Pharmaceuticals, Inc. | ADMA | target | Target of tender offer and merger agreement | 2021-10-12 | View |
| Supernus Reef, Inc. | — | acquirer | Wholly owned subsidiary of Supernus Pharmaceuticals, Inc. acting as the Purchaser in the merger | 2021-10-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Termination of Agreement; Exhibits | View | |
| 2026-10-22 | Other Events; Exhibits | View | |
| 2026-10-19 | Earnings Release | View | |
| 2026-10-15 | Shareholder Vote; Exhibits | View | |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-08-03 | Material Agreement; Officer/Director Change; Other Events; Exhibits | Agreement | View |
| 2026-08-03 | Other Events; Exhibits | View | |
| 2026-08-03 | Other Events; Exhibits | View | |
| 2026-07-22 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Shareholder Vote; Exhibits | View | |
| 2026-05-20 | Financial Obligation; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-22 | Earnings Release | View | |
| 2026-04-07 | Material Agreement; Acquisition/Disposition; Exhibits | Agreement Acquisition | View |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-24 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-28 | Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-10-21 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR